[Featured Stock] Green Cross MS Soars 17% Amid Infectious Disease Spread in US, China, and India

Human Metapneumovirus Spread, Diagnostic Kit Stocks in Focus
Increase in HMPV Cases, Spreading in the US, China, India, and More
Leading Diagnostic Business with Over 40 Years of History

Green Cross MS is showing strong performance. As the infection of 'Human Metapneumovirus' (HMPV), one of the respiratory infectious diseases, spreads from China to India, the United States, and Malaysia, diagnostic kit stocks are gaining attention.

As of 10:50 AM on the 8th, Green Cross MS is trading at 4,815 KRW, up 17.73% (725 KRW) from the previous trading day. The stock hit a high of 5,150 KRW early in the session and is currently undergoing a slight correction. This is the first time since August last year that the stock price has surpassed 5,000 KRW during trading hours.

HMPV is raising alarms worldwide. In the United States, the weekly test positivity rate at the end of last year was 1.94%, and the rate is gradually increasing. India is also seeing a rise in confirmed cases, and reports indicate that the HMPV positivity detection rate is increasing in China as well. Discovered in 2001, HMPV primarily infects infants and young children, causing acute respiratory symptoms such as pneumonia and fever.

Green Cross MS started in 1972 as the diagnostic business division of Green Cross, was established as an independent corporation in the diagnostic reagent field in 2003, and was listed on KOSDAQ in 2014. It has led the domestic diagnostic business sector for about 40 years. The company generates its main revenue through the sales of in vitro diagnostic reagents, medical devices, and hemodialysis fluids. It also gained attention by producing diagnostic kits during the COVID-19 pandemic.

This content was produced with the assistance of AI translation services.